Latest Paradigm Biocapital Advisors LP Stock Portfolio
Paradigm Biocapital Advisors LP Performance:
2025 Q4: 27.37%YTD: 33.45%2024: 10.07%
Performance for 2025 Q4 is 27.37%, and YTD is 33.45%, and 2024 is 10.07%.
About Paradigm Biocapital Advisors LP and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Paradigm Biocapital Advisors LP reported an equity portfolio of $3.9 Billions as of 31 Dec, 2025.
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, RVMD, ACLX. The fund has invested 13.5% of it's portfolio in NUVALENT INC and 13.5% of portfolio in REVOLUTION MEDICINES INC .
The fund managers got completely rid off MERUS N V (MRUS), AGIOS PHARMACEUTICALS INC (AGIO) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in VIRIDIAN THERAPEUTICS INC (VRDN), APOGEE THERAPEUTICS INC and CIDARA THERAPEUTICS INC (CDTX). Paradigm Biocapital Advisors LP opened new stock positions in ORUKA THERAPEUTICS INC, TERNS PHARMACEUTICALS INC (TERN) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), EYEPOINT INC (EYPT) and SCHOLAR ROCK HLDG CORP (SRRK).
The top stock holdings of Paradigm Biocapital Advisors LP are NUVL, RVMD, ACLX. The fund has invested 13.5% of it's portfolio in NUVALENT INC and 13.5% of portfolio in REVOLUTION MEDICINES INC .
The fund managers got completely rid off MERUS N V (MRUS), AGIOS PHARMACEUTICALS INC (AGIO) and JANUX THERAPEUTICS INC (JANX) stocks. They significantly reduced their stock positions in VIRIDIAN THERAPEUTICS INC (VRDN), APOGEE THERAPEUTICS INC and CIDARA THERAPEUTICS INC (CDTX). Paradigm Biocapital Advisors LP opened new stock positions in ORUKA THERAPEUTICS INC, TERNS PHARMACEUTICALS INC (TERN) and VOR BIOPHARMA INC (VOR). The fund showed a lot of confidence in some stocks as they added substantially to GENMAB A/S (GMAB), EYEPOINT INC (EYPT) and SCHOLAR ROCK HLDG CORP (SRRK).
Paradigm Biocapital Advisors LP Annual Return Estimates Vs S&P 500
Our best estimate is that Paradigm Biocapital Advisors LP made a return of 27.37% in the last quarter. In trailing 12 months, it's portfolio return was 33.45%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| oruka therapeutics inc | 51,839,700 |
| lexeo therapeutics inc | 47,298,600 |
| terns pharmaceuticals inc | 32,735,600 |
| vor biopharma inc | 22,890,000 |
| assembly biosciences inc | 22,625,200 |
| oric pharmaceuticals inc | 19,642,000 |
| inventiva sa | 18,600,000 |
| kalaris therapeutics inc | 5,908,000 |
New stocks bought by Paradigm Biocapital Advisors LP
Additions
| Ticker | % Inc. |
|---|---|
| genmab a/s | 84.44 |
| eyepoint inc | 84.08 |
| scholar rock hldg corp | 52.37 |
| arcellx inc | 23.12 |
| bridgebio oncology therapeut | 21.2 |
| olema pharmaceuticals inc | 11.04 |
| vaxcyte inc | 7.48 |
| revolution medicines inc | 6.77 |
Additions to existing portfolio by Paradigm Biocapital Advisors LP
Reductions
| Ticker | % Reduced |
|---|---|
| viridian therapeutics inc | -44.7 |
| apogee therapeutics inc | -26.19 |
| cidara therapeutics inc | -20.97 |
| ocular therapeutix inc | -16.07 |
| crinetics pharmaceuticals in | -13.33 |
| abivax sa | -9.38 |
| tarsus pharmaceuticals inc | -3.88 |
Paradigm Biocapital Advisors LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| merus n v | -411,790,000 |
| cogent biosciences inc | -45,325,900 |
| tango therapeutics inc | -25,923,900 |
| janux therapeutics inc | -71,371,100 |
| agios pharmaceuticals inc | -107,316,000 |
| amylyx pharmaceuticals inc | -25,821,000 |
| dyne therapeutics inc | -24,021,700 |
| pharvaris n v | -45,795,600 |
Paradigm Biocapital Advisors LP got rid off the above stocks
Sector Distribution
Paradigm Biocapital Advisors LP has about 82.7% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 82.7 |
| Others | 17.3 |
Market Cap. Distribution
Paradigm Biocapital Advisors LP has about 15.6% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- LARGE-CAP
- SMALL-CAP
| Category | % |
|---|---|
| MID-CAP | 54.8 |
| UNALLOCATED | 17.3 |
| LARGE-CAP | 15.6 |
| SMALL-CAP | 11.7 |
Stocks belong to which Index?
About 76.4% of the stocks held by Paradigm Biocapital Advisors LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 76.4 |
| Others | 23.6 |
Paradigm Biocapital Advisors LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Paradigm Biocapital Advisors LP
Paradigm Biocapital Advisors LP has 29 stocks in it's portfolio. About 70.4% of the portfolio is in top 10 stocks. ACLX proved to be the most loss making stock for the portfolio. RVMD was the most profitable stock for Paradigm Biocapital Advisors LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 9.53 | 5,724,020 | 373,206,000 | added | 23.12 | ||
| AGIO | agios pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AGLE | spyre therapeutics inc | 1.23 | 1,467,270 | 48,067,600 | unchanged | 0.00 | ||
| ALKS | alkermes plc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMLX | amylyx pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ASMB | assembly biosciences inc | 0.58 | 665,251 | 22,625,200 | new | |||
| BBIO | bridgebio pharma inc | 1.34 | 684,277 | 52,340,300 | unchanged | 0.00 | ||
| CDTX | cidara therapeutics inc | 4.28 | 759,565 | 167,780,000 | reduced | -20.97 | ||
| COGT | cogent biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CRNX | crinetics pharmaceuticals in | 2.63 | 2,210,770 | 102,912,000 | reduced | -13.33 | ||
| DYN | dyne therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ERAS | erasca inc | 1.34 | 14,159,100 | 52,671,800 | added | 4.42 | ||
| EWTX | edgewise therapeutics inc | 4.14 | 6,541,210 | 162,320,000 | added | 6.01 | ||
| EYPT | eyepoint inc | 1.72 | 3,691,480 | 67,443,200 | added | 84.08 | ||
| GMAB | genmab a/s | 5.53 | 7,039,830 | 216,827,000 | added | 84.44 | ||
| IVA | inventiva sa | 0.48 | 4,000,000 | 18,600,000 | new | |||
| JANX | janux therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| NUVL | nuvalent inc | 13.53 | 5,269,430 | 530,052,000 | unchanged | 0.00 | ||
| OCUL | ocular therapeutix inc | 0.91 | 2,935,280 | 35,634,300 | reduced | -16.07 | ||